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A positive association between vascular endothelial growth factor-C (VEGF-C) expression and lymph node metastasis has been
reported in several cancers. However, the relationship of VEGF-C and lymph node metastasis in some cancers, including non-small
cell lung cancer (NSCLC), is controversial. We evaluated the VEGF-C and vascular endothelial growth factor receptor-3 (VEGFR-3)
expression in NSCLC samples from patients who had undergone surgery between 1998 and 2002 using real-time quantitative RT–
PCR and immunohistochemical staining. We failed to find a positive association between VEGF-C and VEGFR-3 mRNA expression
and lymph node metastasis in NSCLC. An immunohistological study demonstrated that VEGF-C was expressed not only in cancer
cells, but also in macrophages in NSCLC, and that VEGFR-3 was expressed in cancer cells, macrophages, type II pneumocytes and
lymph vessels. The VEGF-C/VEGFR-3 ratio of the node-positive group was significantly higher than that of the node-negative group.
Immunohistochemical staining showed that VEGFR-3 was mainly expressed in cancer cells. The immunoreactivity of VEGF-C and
VEGFR-3 was roughly correlated to the mRNA levels of VEGF-C and VEGFR-3 in real-time PCR. VEGF-C mRNA alone has no
positive association with lymph node metastasis in NSCLC. The VEGF-C/VEGFR-3 ratio was positively associated with lymph node
metastasis in NSCLC. This suggests that VEGF-C promotes lymph node metastasis while being influenced by the strength of the
VEGF-C autocrine loop, and the VEGF-C/VEGFR-3 ratio can be a useful predictor of lymph node metastasis in NSCLC.
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Lung cancer is the leading cause of death due to malignant disease
in the developed world. The extent of lymph node metastasis is a
predictor of prognosis (Mountain, 1997). Recently, the assessment
of lymphangiogenesis and lymph node metastasis of neoplasms
has become possible with the development of lymphatic vessel-
specific markers, such as LYVE-1, Prox-1, Podoplanin and D2–40
(Banerji et al, 1999; Weninger et al, 1999; Wigle and Oliver, 1999;
Kahn et al, 2002), and with the elucidation of the role of vascular
endothelial growth factor-C (VEGF-C) and vascular endothelial
growth factor receptor-3 (VEGFR-3) in lymphangiogenesis. How-
ever, many questions remain to be addressed about the mechan-
isms of lymphatic metastasis. VEGF-C is the lymphangiogenic
factor that activates VEGFR-2 and VEGFR-3 in lymphatic
endothelial cells (Jeltsch et al, 1997). VEGF-C/VEGFR-3 signaling
plays a crucial role in the growth and survival of human lymphatic
endothelial cells through mitogen-activated protein kinase and
phosphatidylinositol 3-kinase signaling pathways (Makinen et al,
2001). Overexpression of VEGF-C in cancer cells results in the
enlargement of peritumoral lymphatic vessels and in increased
intratumoral lymphangiogenesis, which promotes cancer meta-
stasis to regional lymph nodes (Skobe et al, 2001). A positive
association of VEGF-C expression with lymph node metastasis
has been reported in several cancers. However, previous immuno-
histochemical studies could not produce a consensus about the
role of VEGF-C in non-small cell lung cancer (NSCLC) (Kajita
et al, 2001; Arinaga et al, 2003; Ogawa et al, 2004). Therefore,
we assessed the expression of VEGF-C and VEGFR-3 mRNA in
NSCLC by real-time quantitative RT–PCR to demonstrate how
they correlated with clinicopathological factors, including lymph
node metastasis.
MATERIALS AND METHODS
Patients
Tissue samples were obtained from 74 patients with NSCLC who
underwent surgery at Tokushima University Hospital from 1998 to
2002. Patients who underwent preoperative therapy were excluded.
Tissue samples were immediately frozen in liquid nitrogen and
stored at  801C until RNA extraction. The patients included 54
males and 20 females, and they ranged in age from 33 to 83
(average age, 67 years). The pathological types were 39 adeno-
carcinomas, 32 squamous cell carcinomas and three large cell
carcinomas, according to World Health Organization (WHO)
recommendations (The World Heath Organization histological
typing of lung tumors. Second edition, 1982). The pathological
stages were classified as stage I in 39 patients, II in 12, III in 20 and
IV in three, according to the International Staging System for Lung
Cancer (Mountain, 1997). (Table 1).
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sRNA extraction and cDNA synthesis
Total RNA was extracted from tissue specimens using the RNeasy
Kit (Qiagen, Tokyo, Japan) according to the recommendations of
the manufacturers protocol. Complementary DNA (cDNA) was
transcribed from the mRNA using Sensiscript Reverse Trancrip-
tase (Qiagen, Japan) and Oligo-dt primers (Gibco BRL, Karlsruhe,
Germany) according to the manufacturer’s protocols.
Real-time quantitative PCR
The levels of VEGF-C mRNA, VEGFR-3 mRNA, and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) mRNA were deter-
mined by real-time quantitative PCR. cDNA samples (2mg) were
used as the template for amplification reactions carried out with
the LC Fast Start DNA master Sybr Green I kit (Roche Applied
Science, Mannheim, Germany) following the manufacturer’s
instructions. PCR amplification was carried out in a Light Cycler
System (Roche, Mannheim, Germany). After an initial denatura-
tion for 10min at 951C, the samples were run for 40 cycles at 951C
(15s), 591C (10s) and 721C (12s). Data was analysed with
LightCycler software 3 version 3.5.28 (Idaho Technology Inc.).
For analysis purposes, the amplicon for each of the analysed genes
was cloned, and known amounts of the cloned product were used
to generate a standard curve. The number of copies of the gene of
interest in each sample was extrapolated from the corresponding
standard curve using the indicated software. For each sample,
duplicate determinations were made, and mean values were adopted
for further calculations. GAPDH was used as an internal control.
Values of VEGF-C and VEGFR-3 mRNA were divided by that of
GAPDH mRNA from the same sample. The sequences of the
primers were (50–30): VEGF-C, forward (50-GACTCAACAGATGGA
TTCC-30) and reverse (50-GGGCAGGTTCTTTTACAT-30); VEGFR-3,
forward (50-CTACAAAGACCCCGACTACG-30) and reverse (50-CGT
AGTCGGGGTCTTTGTAG-3’); and GAPDH, forward (50-CAACAGC
CTCAAGATCATCAGC-3’) and reverse (50-TTCTAGACGGCAGGTC
AGGTC-30).
We confirmed that each PCR product of VEGF-C, VEGFR-3 and
GAPDH was a single band by agarose gel before Light Cycler
System examination.
Immunohistochemistry
Immunohistochemical stainings for VEGF-C and VEGFR-3 were
performed using the streptavidin–biotin–peroxidase complex
method. Formalin-fixed and paraffin-embedded sections of tumour
tissues from resected lung were cut to a thickness of 4mm and
placed on silane-coated slides. After deparaffinization in xylene and
rehydration in graded ethanol, endogeneous peroxydase was
blocked by incubation with 3% hydrogen peroxidase for 30min.
Tissue sections were autoclaved at 1211Ci n1 0 0m M citrate buffer,
pH 6.0, for 20min to expose the antigenic epitopes, and cooled at
room temperature for 30min. The sections were immersed in
normal goat serum for 15min at room temperature. Sections were
incubated for 12h at 41C with a 1:40 dilution of anti-VEGF-C rabbit
polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) or with a 1:100 dilution of anti-VEGFR-3 rabbit polyclonal
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
followed by incubation with biotinylated secondary antibody, and
streptavidin–biotin complex (DAKO LSABþsystem, DAKO Co,
Carpinteria, CA, USA). The sections were developed with diamino-
benzidine and nuclei were counterstained with haematoxylin.
Statistical analysis
The data were expressed as means7s.d.s. An unpaired t-test was
used to analyse VEGF-C and VEGFR-3 mRNA expression, and the
VEGF-C/VEGFR-3 ratio for each clinicopathological factor; age
(70o vs 70X), gender (male vs female), T factor (T1 vs T2), N
factor (N  vs Nþ), stage (I and II vs III and IV), histological type
(adenocarcinoma vs squamous cell carcinoma), differentiation
(well vs moderate and poor). A paired t-test was used to analyse
VEGF-C and VEGFR-3 mRNA expression between 10 pairs of
normal and lung cancer tissues (SPSS, version 11.0; SPSS Inc.,
Chicago, IL, USA). Po0.05 was considered statistically significant.
RESULTS
Expression levels of VEGF-C and VEGFR-3 mRNA in
normal lung and lung cancer tissues
We examined VEGF-C and VEGFR-3 mRNA expression levels in
10 pairs of samples of tumour tissues and normal lung tissues that
were distant from the primary tumour. The VEGF-C expression
level was higher in the normal lung tissues than in the tumour
tissues (130.2759.7 vs 65.1746.1, P¼0.03), while there was no
significant difference in the VEGFR-3 expression level between
these tissues (53.57101.4 vs 42.1733.4, P¼0.73). Relative expres-
sion levels of VEGF-C and VEGFR-3 mRNA in 74 tumour tissues
were 42.9751.7 and 52.7799.1, respectively.
The relationship between VEGF-C or VEGFR-3 mRNA expres-
sion and clinicopathological features are shown in Table 2. The
expression level of VEGF-C mRNA in adenocarcinoma was
significantly higher than that in squamous cell carcinoma
Table 1 Patient characteristics
Characteristic No. of patients
Age (mean7s.d.) 67710
Gender
Male 54
Female 20
TNM
T
12 8
23 2
35
49
N
04 8
11 2
21 4
M
07 1
13
Stage
I3 9
II 12
III 20
IV 3
Histological type
Adenocarcinoma 39
Squamous cell ca 32
Large cell ca 3
Differentiation
Adenocarcinoma
Well 16
Moderate 17
Poor 6
Squamous cell ca
Well 6
Moderate 19
Poor 7
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s(P¼0.006). For the N-factor, the node-positive group tended to
have a lower VEGF-C mRNA expression level than the node-
negative group (P¼0.08). There was no significant correlation
between VEGF-C mRNA and the other clinicopathological factors,
including age, gender, T-factor, stage and differentiation. The node-
positive group had significantly lower VEGFR-3 mRNA expression
levels than the node-negative group (P¼0.003). The expression
level of VEGFR-3 mRNA in adenocarcinoma was significantly
higher than that in squamous cell carcinoma (P¼0.003). There was
no significant correlation between the VEGFR-3 mRNA level and
other clinicopathological factors (Table 2).
VEGF-C and VEGFR-3 protein levels in normal lung and
lung cancer tissues
To evaluate the location of VEGF-C and/or VEGFR-3 positive cells,
we assessed the VEGF-C and VEGFR-3 protein levels in 14 pairs of
lung cancer tissues and adjacent normal lung tissues by
immunohistochemical methods. VEGF-C was mainly observed in
the cytoplasm of cancer cells and macrophages that had infiltrated
into the stromal tissues. Strong VEGFR-3 immunoreactivity was
frequently present in the cytoplasm of cancer cells. VEGFR-3
immunoreactivity was also present in macrophages and endo-
thelial cells of lymphatic vessels in the stroma surrounding the
cancer cells. When we classified the cases in which more than 50%
of the cancer cells were stained as positive cases, there were seven
positive cases (50%) for VEGF-C and six positive cases (43%) for
VEGFR-3. In normal lung tissues, VEGF-C was observed in
macrophages, and VEGFR-3 was observed in alveolar type II cells
and macrophages (Figure 1). The VEGF-C mRNA expression levels
in the tumour tissues with (n¼7) and without (n¼7) VEGF-C
protein expression were 52.5753.2 and 28.8731.0, respectively.
VEGFR-3 mRNA expression levels in the tumour tissues with
(n¼6) or without (n¼8) VEGFR-3 protein expression were
73.4783.2 and 14.5717.1, respectively. The immunoreactivity of
VEGF-C and VEGFR-3 in cancer cells roughly correlated to the
relative levels of VEGF-C and VEGFR-3 mRNA expression.
Table 2 Correlation between VEGF-C and VEGFR-3 mRNA expression and clinicopathological factor
Clinicopathological factors No. of patients VEGF-C P-value VEGFR-3 P-value
Age
704 40 50.8758.3 0.15 70.87128.2 0.07
70p 34 33.6741.5 31.3738.0
Gender
Male 54 41.2749.1 0.64 35.4753.4 0.1
Female 20 47.5759.3 99.37163.3
T
1 28 51.7762.3 0.17 85.97148.9 0.09
2 32 32.5744.8 34.4743.7
N
( ) 48 50.6757.0 0.08 71.77118.2 0.003
(+) 26 28.7737.0 17.5721.6
Stage
I, II 51 48.3757.5 0.11 66.17116.1 0.08
III, IV 23 31.0733.6 22.9725.0
Histological type
Adenocarcinoma 39 56.6760.4 0.006 81.37126.8 0.003
Squamous cell ca 32 24.5733.1 15.3724.4
Differentiation
Adenocarcinoma
Well 16 53.0755.3 0.76 120.27177.3 0.11
Mod or Poor 23 59.1764.8 35.9754.1
Squamous cell ca
Well 6 26.4738.7 0.88 18.3719.5 0.75
Mod or Poor 26 24.0732.6 14.7725.7
VEGF-C: vascular endothelial growth factor-C; VEGFR-3: vascular endothelial growth factor receptor-3.
AB
CD
Figure 1 (A–D) Immunohistochemical staining for VEGF-C and
VEGFR-3. (A) In normal lung tissue, VEGF-C was observed in macrophages
(arrow). (B) In tumor tissue, VEGF-C was mainly observed in the
cytoplasm of the cancer cells and macrophages infiltrated into the stromal
tissues. (C) In normal lung tissue, VEGFR-3 was observed in alveolar type II
cells and macrophages. (D) In tumour tissue, VEGFR-3 immunoreactivity
was present in the cytoplasm of cancer cells, macrophages and endothelial
cells of lymphatic vessels in the stroma surrounding the cancer cells
(arrows).
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In order to evaluate the balance of VEGF-C and VEGFR-3 mRNA
expression levels, we measured the ratio of VEGF-C/VEGFR-3
mRNA expression levels in each lung cancer (Table 3). The VEGF-
C/VEGFR-3 ratio in the node-positive group was significantly
higher than that of the node-negative group (P¼0.03). The VEGF-
C/VEGFR-3 ratio was associated significantly with gender and
histological type (P¼0.006 and 0.04). There was no significant
correlation between VEGF-C mRNA and other clinicopathological
factors, including age, T-factor, stage or differentiation.
DISCUSSION
A positive association of VEGF-C expression with lymph node
metastasis has been reported in head and neck cancer, thyroid
cancer, lung cancer, oesophageal cancer, pancreatic cancer, gastric
cancer, colorectal cancer, ovarian cancer and prostatic cancer
(Bunone et al, 1999; Tsurusaki et al, 1999; Yonemura et al, 1999;
Kajita et al, 2001; Kitadai et al, 2001; Tang et al, 2001; Kawakami
et al, 2003; Neuchrist et al, 2003; Yokoyama et al, 2003). However,
some types of cancer, including lung cancer, did not demonstrate a
positive association of VEGF-C with lymph node metastasis
(Arinaga et al, 2003; van Trappen et al, 2003; Ogawa et al, 2004).
This study demonstrated that VEGF-C was expressed not only
in cancer cells, but also in macrophages in NSCLC, using immuno-
histochemistry, and that VEGFR-3 was expressed in cancer cells
and macrophages, type II pneumocytes and lymph vessels. Lung
cancer cells expressed not only VEGF-C, but also VEGFR-3. Several
previous studies of NSCLC demonstrated that VEGF-C is expressed
in tumour cells (Kajita et al, 2001; Arinaga et al, 2003; Ogawa et al,
2004) and stromal macrophages (Arinaga et al, 2003; Ogawa et al,
2004), and that VEGFR-3 was observed in the cytoplasm of tumour
cells (Kajita et al, 2001; Arinaga et al, 2003), lymphatic vessels
(Niki et al, 2000; Kajita et al, 2001) and macrophages (Arinaga
et al, 2003) using immunohistochemical methods. Our immuno-
histochemical results in NSCLC agree with these previous results.
Therefore, we expected that a complex interaction was occurring
between VEGF-C and VEGFR-3 in both normal and cancer cells in
NSCLC. To comprehensively evaluate this interaction between
VEGF-C and VEGFR-3 in the complex cellular environment, we
assessed the expression levels of VEGF-C and VEGFR-3 mRNA by
real-time quantitative RT–PCR in NSCLC.
Our results failed to find a positive association between VEGF-C
and VEGFR-3 mRNA expression levels and lymph node metastasis
in NSCLC. Patients with lymph node metastasis tended to have
a lower VEGF-C mRNA expression level than those without
metastasis. Arinaga and Ogawa also reported that there was no
significant correlation between the VEGF-C expression level and
lymph node metastasis (Arinaga et al, 2003; Ogawa et al, 2004) On
the other hand, Kajita demonstrated a positive association between
VEGF-C expression level and lymph node metastasis using
immunohistochemical methods (Kajita et al, 2001). These findings
suggest that VEGF-C expression levels in the tumour alone cannot
predict lymph node metastasis in NSCLC. We suspect that this
may be due to the complex environment of the VEGF-C and
VEGFR-3 interaction in NSCLC. This study demonstrated that
some lung cancers expressed both of VEGF-C and VEGFR-3 at the
protein (29%: data not shown) and mRNA level (19%). This data
suggests that there is an autocrine pathway between VEGF-C and
VEGFR-3 in NSCLC.
Some studies demonstrated an autocrine pathway between
VEGF-C and VEGFR-3 in cervical cancer and mesothelioma. Van
Trappen reported that more than 50% of cervical cancer in an
advanced stage, which frequently had lymphogenous metastasis,
expressed VEGF-C and/or VEGFR-3 proteins, and that this
suggested an autocrine growth stimulation pattern via VEGFR-3
in cervical cancer (van Trappen et al, 2003). Masood et al (2003)
reported that reduced levels of VEGF-C inhibit mesothelioma cell
growth in vitro, and that antibodies to VEGFR-3 inhibited
mesothelioma cell growth. These results indicated that a functional
VEGF-C autocrine growth loop is functioning in mesothelioma
cells. We speculate that in tumour cells that express both VEGF-C
and VEGFR-3, the secreted VEGF-C mainly binds to VEGFR-3
on the tumour cells themselves (autocrine loop), and that only
residual VEGF-C binds to the VEGFR-3 receptors in lymphatic
endothelial cells (paracrine pathway) and promotes lymphangio-
genesis. Schoppmann et al (2002) reported that stromal macro-
phages expressed VEGF-C and played important roles in
peritumoral lymphangiogenesis. We suspect that the balance of
VEGF-C and VEGFR-3 expression in the environment of NSCLC
affects the lymphangiogenesis. When the amount of VEGF-C
secreted by the tumour cells and macrophages overtakes the
amount of VEGFR-3 in cancer cells, macrophages and type II
pneumocytes, lymphangiogenesis is promoted and lymphogenous
metastasis is increased. In this study, we evaluated the relative
amount of VEGF-C and VEGFR-3 expression in tumour tissues
and lymphogenous metastasis in NSCLC. The VEGF-C/VEGFR-3
ratio of the node-positive group was significantly higher than that
of the node-negative group (3.6674.05 vs 1.7772.44, P¼0.03).
The VEGF-C/VEGFR-3 ratio is a parameter of the balance between
VEGF-C and VEGFR-3 expression in tumour tissues. This result
suggests that when VEGF-C expression is relatively higher than
VEGFR-3 expression, lymph node metastasis is promoted. A
previous report demonstrated that the serum VEGF-C level of
patients with lymph node metastasis was significantly higher than
that of patients without metastasis in NSCLC (Tamura and Ohta,
2003). This study supports our speculation. We think that when
Table 3 Correlation between VEGF-C/VEGFR-3 and clinicopathological
factors
Clinicopathological
factors
No. of
patients
VEGF-C/
VEGFR-3 P-value
Age
704 40 2.2472.89 0.58
70p 34 2.6673.57
Gender
Male 54 2.8873.57 0.006
Female 20 1.2471.38
T
1 28 1.7972.22 0.27
2 32 2.7273.84
N
( ) 48 1.7772.44 0.03
(+) 26 3.6674.05
Stage
I, II 51 2.1972.84 0.34
III, IV 23 2.9773.91
Histological type
Adenocarcinoma 39 1.7072.02 0.04
Squamous cell ca 32 3.4073.40
Differentiation
Adenocarcinoma
Well 16 1.0871.12 0.08
Mod or Poor 23 2.1272.39
Squamous cell ca
Well 6 1.5870.92 0.24
Mod or Poor 26 3.8274.49
VEGF-C: vascular endothelial growth factor-C; VEGFR-3: vascular endothelial growth
factor receptor-3.
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bind to VEGFR-3 in the cancer cells, it binds to VEGFR-3 in lymph
vessels, promoting lymphangiogenesis and lymph node metastasis.
In conclusion, tumour cells expressed both VEGF-C and
VEGFR-3 in NSCLC (autocrine loop), and other normal cells
(macrophages, type II pneumocytes and lymph vessels) also
expressed VEGF-C and/or VEGFR-3. In this complex environment,
VEGF-C expression levels alone cannot predict lymph node
metastasis. The balance of VEGF-C and VEGFR-3 expression
levels in the tumour tissues affects the lymph node metastasis. The
VEGF-C/VEGFR-3 ratio can be a useful predictor of lymph node
metastasis in NSCLC.
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